Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.39 USD
+0.07 (5.30%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Coherus BioSciences (CHRS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.21 | $12.00 | $1.50 | 446.21% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Coherus BioSciences comes to $7.21. The forecasts range from a low of $1.50 to a high of $12.00. The average price target represents an increase of 446.21% from the last closing price of $1.32.
Analyst Price Targets (7 )
Broker Rating
Coherus BioSciences currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, six are Strong Buy, representing 60% of all recommendations. A month ago, Strong Buy represented 70%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.80 | 1.80 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/19/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/16/2024 | UBS | Ashwani Verma | Strong Buy | Hold |
8/5/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
7/1/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
5/18/2024 | Maxim Group | Michael Okunewitch | Hold | Hold |
5/13/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Michael Nedelcovych | Strong Buy | Strong Buy |
10/30/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 10 |
Average Target Price | $7.21 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.07 |